<DOC>
	<DOCNO>NCT01061606</DOCNO>
	<brief_summary>This phase II trial study well temsirolimus work treat patient recurrent persistent cancer uterus . Temsirolimus may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Temsirolimus Treating Patients With Recurrent Persistent Cancer Uterus</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Assess efficacy Temsirolimus woman recurrent persistent ( primary therapy ) Carcinosarcoma ( MMMT ) uterus . II . Assess safety tolerability Temsirolimus patient population . III . Evaluate secondary efficacy endpoint time tumor progression , progression-free survival ( PFS ) , 6 month PFS rate , duration response . SECONDARY OBJECTIVES : I . Overall survival II.Duration Response III . Time progression IV . Time treatment failure OUTLINE : This multicenter study . Patients receive temsirolimus IV 30 minute day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically 3 year .</detailed_description>
	<mesh_term>Carcinosarcoma</mesh_term>
	<mesh_term>Mixed Tumor , Mullerian</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically cytologically confirm Carcinosarcoma ( MMMT ) Measurable disease ; Only one prior systemic treatment primary adjuvant treatment persistent metastatic disease permit , Radiation therapy ( adjuvant palliative ) must complete ≥ 4 week prior registration Required laboratory value obtain = &lt; 7 day prior registration : Absolute Neutrophil Count ( ANC ) &gt; = 1500/mm^3 Platelets &gt; = 75,000/mm^3 Hemoglobin &gt; = 9.0 g/dL Direct bilirubin = &lt; 1.5 x upper limit normal ( ULN ) Alkaline phosphatase = &lt; 2.5 x ULN ( ≤ 5 x ULN liver metastasis present ) SGOT ( AST ) = &lt; 2.5 x ULN ( ≤ 5 x ULN liver metastasis present ) Creatinine = &lt; 1.5 x ULN Fasting serum cholesterol ≤ 350mg/dL ( 9.0 mmol/L ) Triglycerides ≤ 1.5 x ULN Patients Triglyceride level &gt; 1.5 x ULN start lipid lower agent reevaluate within 1 week ; level go ≤ 1.5 x ULN , consider trial continue lipid lowering agent International Normalized Ratio ( INR ) ≤ 1.5 ( unless patient full dose warfarin ) ECOG Performance Status ( PS ) 01 Capable understanding investigational nature , potential risk benefit study able provide valid inform consent Fulldose anticoagulant , patient receive fulldose anticoagulant , follow criterion meet enrollment : The subject must inrange INR ( usually 2 3 ) stable dose warfarin stable dose LMW heparin Patients prior anthracycline must normal ejection fraction LVEF assessment MUGA Echo ≤ 4 week prior registration Availability tissue sample block ( primary tumor metastasis ) tumor study Willingness donate blood correlative marker study Prior therapy Temsirolimus another mTOR inhibitor Patients receive enzymeinducing antiepileptic drug ( EIAEDs ; e.g. , phenytoin , carbamazepine , phenobarbital ) CYP3A4 inducer rifampin St. John 's wort Untreated central nervous system ( CNS ) metastases ; exception : patient know CNS metastasis enrol brain metastasis adequately treat evidence progression hemorrhage treatment ascertain clinical examination brain imaging ( MRI CT ) ≤ 12 week prior registration ongoing requirement steroid Anticonvulsants ( stable dose ) allow Patients surgical resection CNS metastases brain biopsy ≤ 3 month prior registration exclude Pregnant lactate wome Currently active , second malignancy nonmelanoma skin cancer ; Other uncontrolled serious medical psychiatric condition ( e.g . cardiac arrhythmia , diabetes , etc . ) Active infection require antibiotic Received prior radiotherapy portion abdominal cavity pelvis OTHER THAN treatment endometrial cancer Radiation therapy &gt; 50 % marrow bearing area</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>